美国 · SEC FORM 4
INCYTE CORP
INCY · Nasdaq · CIK 0000879169 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
93 同一窗口内观察到的 Form 4 交易行
25 sales · 68 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2022-03-10 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP · $16.0M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Mayes Patrick AEVP & Chief Scientific Officer
○○○○▼○▼○▼
CAGNONI PABLO JPresident, Global Head of R&D
○▼▼▼▼○▼
Stein Steven HCMO & Head of Late-Stage Dev.
○○▼○▼
Tray ThomasPrincipal Accounting Officer
○○○
Issa Mohamed KhairieEVP, Head of U.S. Commercial
○○▼
Gardner David HEVP, Chief Strategy Officer
○○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 7 additional owner(s) remain in Form 4 申报证据.
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2022-03-10 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP.
近期 Form 4 活动
0买入
46卖出
100其他 Form 4 交易行
81SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出25 sale line(s) · 仅供背景
其他68 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 9,987,084
- 上期报告
- 9,981,369
- 日均成交量
- 1,647,341
- 回补天数
- 6.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2022-03-10 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 218,563 | USD 73.13 | USD 15,983,037 | SEC 申报 ↗ |
| 2022-03-09 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 70,517 | USD 71.72 | USD 5,057,479 | SEC 申报 ↗ |
| 2022-03-08 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 100,000 | USD 70.68 | USD 7,068,000 | SEC 申报 ↗ |
| 2022-02-22 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 99,800 | USD 68.07 | USD 6,793,386 | SEC 申报 ↗ |
| 2022-02-18 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 133,032 | USD 68.38 | USD 9,096,838 | SEC 申报 ↗ |
| 2022-02-17 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 292,972 | USD 67.73 | USD 19,843,441 | SEC 申报 ↗ |
| 2022-02-14 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 502,852 | USD 66.03 | USD 33,201,936 | SEC 申报 ↗ |
| 2022-02-11 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 276,507 | USD 66.82 | USD 18,474,971 | SEC 申报 ↗ |
| 2022-02-10 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 819,015 | USD 67.49 | USD 55,275,240 | SEC 申报 ↗ |
| 2021-12-17 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 1,075,872 | USD 72.80 | USD 78,318,365 | SEC 申报 ↗ |
| 2021-12-16 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 169,315 | USD 71.97 | USD 12,185,096 | SEC 申报 ↗ |
| 2021-12-15 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 350,332 | USD 71.51 | USD 25,052,795 | SEC 申报 ↗ |
| 2021-02-23 | Hoppenot Herve | 买入 (P) | Common Stock | 12,925 | USD 77.37 | USD 1,000,007 | SEC 申报 ↗ |
| 2020-05-28 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 1 | USD 102.55 | USD 103 | SEC 申报 ↗ |
Form 4 申报证据
146 transaction lines in the latest 365-day window; 909 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Heeson Lee | 代扣税 (F) | Common Stock | 463 | USD 117.14 | USD 54,236 | SEC 申报 ↗ |
| 2026-09-30 | HARRIGAN EDMUND | 奖励／授予 (A) | Common Stock | 206 | USD 121.35 | USD 24,998 | SEC 申报 ↗ |
| 2026-09-30 | Clancy Paul J | 奖励／授予 (A) | Common Stock | 203 | USD 121.35 | USD 24,634 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Heeson Lee | 代扣税 (F) | Common Stock | 463 | USD 117.14 | USD 54,236 | SEC 申报 ↗ |
| 2026-09-30 | HARRIGAN EDMUND | 奖励／授予 (A) | Common Stock | 206 | USD 121.35 | USD 24,998 | SEC 申报 ↗ |
| 2026-09-30 | Clancy Paul J | 奖励／授予 (A) | Common Stock | 203 | USD 121.35 | USD 24,634 | SEC 申报 ↗ |
| 2026-09-30 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 奖励／授予 (A) | Common Stock | 322 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-22 | Gardner David H | 代扣税 (F) | Common Stock | 920 | USD 126.93 | USD 116,776 | SEC 申报 ↗ |
| 2026-09-15 | CAGNONI PABLO J | 卖出 (S) | Common Stock | 23,218 | USD 120.49 | USD 2,797,629 | SEC 申报 ↗ |
| 2026-09-15 | CAGNONI PABLO J | 期权行权／转换 (M) | Common Stock | 23,218 | USD 66.39 | USD 1,541,331 | SEC 申报 ↗ |
| 2026-08-25 | Basi Ramitpal K | 代扣税 (F) | Common Stock | 504 | USD 129.72 | USD 65,379 | SEC 申报 ↗ |
| 2026-08-19 | CAGNONI PABLO J | 卖出 (S) | Common Stock | 10,801 | USD 125.56 | USD 1,356,174 | SEC 申报 ↗ |
| 2026-08-12 | CAGNONI PABLO J | 卖出 (S) | Common Stock | 10,803 | USD 120.04 | USD 1,296,792 | SEC 申报 ↗ |
| 2026-08-05 | Mayes Patrick A | 卖出 (S) | Common Stock | 2,207 | USD 123.99 | USD 273,646 | SEC 申报 ↗ |
| 2026-08-05 | Mayes Patrick A | 期权行权／转换 (M) | Common Stock | 2,207 | USD 106.47 | USD 234,979 | SEC 申报 ↗ |
| 2026-08-05 | CAGNONI PABLO J | 卖出 (S) | Common Stock | 10,640 | USD 122.69 | USD 1,305,422 | SEC 申报 ↗ |
| 2026-08-03 | Mayes Patrick A | 卖出 (S) | Common Stock | 6,055 | USD 120.43 | USD 729,204 | SEC 申报 ↗ |
| 2026-08-03 | Mayes Patrick A | 期权行权／转换 (M) | Common Stock | 6,055 | USD 105.43 | USD 638,379 | SEC 申报 ↗ |
| 2026-07-31 | Mayes Patrick A | 卖出 (S) | Common Stock | 41,899 | USD 119.46 | USD 5,005,173 | SEC 申报 ↗ |
| 2026-07-31 | Mayes Patrick A | 期权行权／转换 (M) | Common Stock | 39,712 | USD 74.37 | USD 2,953,496 | SEC 申报 ↗ |
| 2026-07-31 | CAGNONI PABLO J | 卖出 (S) | Common Stock | 15,888 | USD 119.70 | USD 1,901,794 | SEC 申报 ↗ |
| 2026-07-16 | Tray Thomas | 奖励／授予 (A) | Common Stock | 2,834 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Stein Steven H | 卖出 (S) | Common Stock | 1,877 | USD 114.73 | USD 215,348 | SEC 申报 ↗ |
| 2026-07-16 | Stein Steven H | 奖励／授予 (A) | Common Stock | 9,798 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Meury William | 奖励／授予 (A) | Common Stock | 26,807 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Mayes Patrick A | 奖励／授予 (A) | Common Stock | 5,916 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Issa Mohamed Khairie | 卖出 (S) | Common Stock | 1,093 | USD 115.01 | USD 125,706 | SEC 申报 ↗ |
| 2026-07-16 | Issa Mohamed Khairie | 奖励／授予 (A) | Common Stock | 7,857 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Hoffman Richard A. | 奖励／授予 (A) | Common Stock | 7,395 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Gardner David H | 奖励／授予 (A) | Common Stock | 7,395 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | CAGNONI PABLO J | 奖励／授予 (A) | Common Stock | 13,403 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Basi Ramitpal K | 奖励／授予 (A) | Common Stock | 4,991 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-15 | Tray Thomas | 代扣税 (F) | Common Stock | 1,098 | USD 115.09 | USD 126,369 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | INCY |
| CIK | 0000879169 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 8731 Services-Commercial Physical & Biological Research |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 909 transaction lines from 2020-01-02 to 2026-10-01 37 P purchase lines · 195 S sale lines · 677 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.